介入放射学杂志
介入放射學雜誌
개입방사학잡지
JOURNAL OF INTERVENTIONAL RADIOLOGY
2014年
6期
528-531
,共4页
原发性肝癌%高尔基体膜蛋白-73%甲胎蛋白%诊断价值
原髮性肝癌%高爾基體膜蛋白-73%甲胎蛋白%診斷價值
원발성간암%고이기체막단백-73%갑태단백%진단개치
primary hepatocellular carcinoma%Golgi protein-73%alpha-fetal protein%diagnosis value
目的：探讨原发性肝癌患者血清中高尔基体膜蛋白-73（Golgi protein-73，GP73）的表达水平及其早期诊断价值。方法收集人外周血血清490例，应用酶联免疫定量测定法和电化学发光法分别检测血清中GP73表达和AFP水平。结果肝细胞肝癌、胆管细胞癌及布加综合征合并肝细胞肝癌患者血清GP73的表达水平均高于其他各组（P<0.05）；GP73、AFP诊断肝细胞肝癌（包括布加综合征合并肝细胞肝癌）的受试者工作特征曲线下面积、灵敏度、特异度、正确率及最佳临界值分别为0.868、90.8%、75.5%、77.6%、43.40 ng/ml；0.739、60%、83.2%、80.2%、20 ng/ml。 GP73诊断肝细胞肝癌的受试者工作特征曲线下面积及灵敏度显著高于AFP（P<0.05）；特异度及正确率差别无统计学意义（P>0.05）。GP73诊断胆管细胞癌的受试者工作特征曲线下面积为0.774，灵敏度、特异度及正确率分别为88.6%、72.7%及73.9%，最佳临界值为45.40 ng/ml。结论血清GP73对原发性肝癌的诊断价值优于AFP，有望成为原发性肝癌早期诊断的血清标记物。
目的：探討原髮性肝癌患者血清中高爾基體膜蛋白-73（Golgi protein-73，GP73）的錶達水平及其早期診斷價值。方法收集人外週血血清490例，應用酶聯免疫定量測定法和電化學髮光法分彆檢測血清中GP73錶達和AFP水平。結果肝細胞肝癌、膽管細胞癌及佈加綜閤徵閤併肝細胞肝癌患者血清GP73的錶達水平均高于其他各組（P<0.05）；GP73、AFP診斷肝細胞肝癌（包括佈加綜閤徵閤併肝細胞肝癌）的受試者工作特徵麯線下麵積、靈敏度、特異度、正確率及最佳臨界值分彆為0.868、90.8%、75.5%、77.6%、43.40 ng/ml；0.739、60%、83.2%、80.2%、20 ng/ml。 GP73診斷肝細胞肝癌的受試者工作特徵麯線下麵積及靈敏度顯著高于AFP（P<0.05）；特異度及正確率差彆無統計學意義（P>0.05）。GP73診斷膽管細胞癌的受試者工作特徵麯線下麵積為0.774，靈敏度、特異度及正確率分彆為88.6%、72.7%及73.9%，最佳臨界值為45.40 ng/ml。結論血清GP73對原髮性肝癌的診斷價值優于AFP，有望成為原髮性肝癌早期診斷的血清標記物。
목적：탐토원발성간암환자혈청중고이기체막단백-73（Golgi protein-73，GP73）적표체수평급기조기진단개치。방법수집인외주혈혈청490례，응용매련면역정량측정법화전화학발광법분별검측혈청중GP73표체화AFP수평。결과간세포간암、담관세포암급포가종합정합병간세포간암환자혈청GP73적표체수평균고우기타각조（P<0.05）；GP73、AFP진단간세포간암（포괄포가종합정합병간세포간암）적수시자공작특정곡선하면적、령민도、특이도、정학솔급최가림계치분별위0.868、90.8%、75.5%、77.6%、43.40 ng/ml；0.739、60%、83.2%、80.2%、20 ng/ml。 GP73진단간세포간암적수시자공작특정곡선하면적급령민도현저고우AFP（P<0.05）；특이도급정학솔차별무통계학의의（P>0.05）。GP73진단담관세포암적수시자공작특정곡선하면적위0.774，령민도、특이도급정학솔분별위88.6%、72.7%급73.9%，최가림계치위45.40 ng/ml。결론혈청GP73대원발성간암적진단개치우우AFP，유망성위원발성간암조기진단적혈청표기물。
Objective To investigate the expression level of serum Golgi protein-73 (GP73) in patients with primary hepatocellular carcinoma (HCC), or accompanied with Budd-Chiari syndrome (BCS), and to discuss its clinical value in making early diagnosis. Methods The peripheral serum samples were collected in 490 individuals, including patients with HCC (n = 65), cholangiocarcinoma (CC, n = 35), Budd-Chiari syndrome accompanied with HCC (n = 40), type B virus hepatitis (n = 60), cirrhosis after B hepatitis (n = 60), Budd-Chiari syndrome complicated by cirrhosis (n = 60), other malignant lesions (n =50), benign hepatic lesions (n = 60) and healthy volunteers (n = 60). The expression levels of serum GP73 and AFP were determined by using Elisa and electrochemiluminescence methods separately. Results The expression level of serum GP73 in the patients with HCC , CC or BCS plus HCC were significantly higher than that in the other individuals (P < 0.05). The area under the receiver operating characteristic curve (ROC), the sensitivity, the specificity and the diagnostic accuracy of GP73 and AFP for HCC were 0.868, 90.8%, 75.5%, 77.6% and 0.739, 60%, 83.2%, 80.2% respectively. The cut-off values of GP73 and AFP were 43.40 ng/ml and 20ng/ml respectively. The area under ROC and the sensitivity of GP73 for the diagnosis of HCC were strikingly higher than those of AFP (P < 0.05), while no significant differences in the specificity and diagnostic accuracy existed between GP73 and AFP (P > 0.05). The area under ROC, sensitivity, specificity and the accuracy of GP73 for the diagnosis of CC were 0.774 , 88.6%, 72.7% and 73.9%respectively, and the optimal cut-off value was 45.40 ng/ml. Conclusion In diagnosing HCC, the expression level of serum GP73 is superior to AFP. It is hopeful that serum GP73 may be proved to be an early serum tumor marker for HCC.
